# Nuclide record follicular-lymphoma (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/follicular-lymphoma/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "follicular-lymphoma" ;
  schema:name "Follicular lymphoma"@en ;
  schema:description "Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."@en ;
  schema:url <https://nuclide.cc/indications/follicular-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Follicular_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q123251> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480>, <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>, <https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/> ;
  nuclide:tag "gap-fill", "haematologic" ;
  nuclide:related <https://nuclide.cc/indications/dlbcl/> ;
  nuclide:technologies <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/radioimmunotherapy/> ;
  nuclide:targets <https://nuclide.cc/targets/cd20/> ;
  nuclide:drugs <https://nuclide.cc/drugs/rituximab/>, <https://nuclide.cc/drugs/ibritumomab-tiuxetan/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/rituximab/>, <https://nuclide.cc/drugs/rituximab/>, <https://nuclide.cc/drugs/rituximab/> .